Mark Kotter, bit.bio CEO
November 5, 2021 10:42 AM EDTUpdated 11:24 AM
Financing

Cell ther­a­py start­up bit.bio adds $100M+ to its cof­fers and some im­pres­sive names to its board of di­rec­tors

Nicole DeFeudis

Editor

Bit.bio CEO Mark Kot­ter says the last ma­jor rev­o­lu­tion in bio­phar­ma oc­curred around the 1980s, when an­ti­bod­ies — or, as some

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times